

121
NOTE 28.11 EMPLOYEE BENEFITS
(continued)
d)
The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority,
promotion and other relevant factors, such as supply and demand in the employment market. Mortality rates
are obtained from the relevant data.
Unfunded Schemes
(
`
cr)
Particulars
Compensated absences
March 31, 2015 March 31, 2014
1 Present value of unfunded obligations
–
21.24
2 Expense recognised in the Statement of Profit and Loss
3.23
3.23
3 Discount rate (per annum)
7.80%
9.29%
4 Salary escalation rate (per annum)
7.00%
7.00%
NOTE 28.12 INTEREST IN JOINT VENTURE COMPANY
The Company acquired 50% interest in Rudolf Kiri Chemicals Pvt Ltd, now called Rudolf Atul Chemicals Ltd (RACL),
a joint venture company in India between IB Industriechemie Beteiligungs GmbH, Germany and Atul Ltd on
August 18, 2011. RACL is engaged in the business of manufacturing and marketing textile chemicals. As per the
contractual arrangement between the Shareholders of RACL, both the companies have significant participating
rights such that they jointly control the operations of the joint venture company. The aggregate amount of assets,
liabilities, income and expenses related to the share of the Company in RACL as at and for the year ended March
31, 2015 as per the audited Financial Statements are given below:
Balance Sheet
as at March 31, 2015
(
`
cr)
Particulars
As at
March 31, 2015
As at
March 31, 2014
Current liabilities
Trade payables
3.41
2.44
Other current liabilities
0.43
0.38
Short-term provisions
0.73
0.52
4.57
3.34
Total (A)
4.57
3.34
Non-current assets
Tangible assets, net
0.27
0.25
Intangible assets, net
0.01
0.36
Capital work-in-progress
0.11
–
Deferred tax assets (net) (Previous year:
`
3,654)
0.08
Long-term loans and advances
1.41
1.42
1.88
2.03
Current assets
Inventories
2.79
2.05
Trade receivables
5.35
3.95
Cash and cash equivalents
3.77
2.51
Short-term loans and advances
0.14
0.12
Other current assets
0.61
0.59
12.66
9.22
Total (B)
14.54
11.25
Net worth (B-A)
9.97
7.91
Notes
to the Financial Statements